Hepatitis C virus treatment for prevention among people who inject drugs: Modeling treatment scale-up in the age of direct-acting antivirals

Hepatology

Volumn 58, Issue 5, 2013, Pages 1598-1609

  Martin, Natasha K ^a,b   Vickerman, Peter ^b   Grebely, Jason ^c   Hellard, Margaret ^d   Hutchinson, Sharon J ^e,f   Lima, Viviane D ^g   Foster, Graham R ^h   Dillon, John F ⁱ   Goldberg, David J ^e   Dore, Gregory J ^c   Hickman, Matthew ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c UNIVERSITY OF NEW SOUTH WALES   (Australia)

^d BURNET INSTITUTE   (Australia)

^e HEALTH PROTECTION SCOTLAND   (United Kingdom)

^f GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^g UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^h QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

ⁱ UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; PEGINTERFERON; RIBAVIRIN;

ARTICLE; AUSTRALIA; BUDGET; CANADA; DRUG COST; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; PREVALENCE; PRIORITY JOURNAL; SCALE UP; TREATMENT DURATION; TREATMENT RESPONSE; UNITED KINGDOM; VIRUS TRANSMISSION;

ANTIVIRAL AGENTS; HEPATITIS C; HUMANS; MODELS, THEORETICAL; PREVALENCE; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84887020007     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.26431     Document Type: Article

References (63)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infec Dis 2005;5:558-567.
2. Ly KN, Xing J, Klevens RM, Jiles RB, Ward JW, Holmberg SD. The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Int Med 2012;156:271-278.
3. Nelson PK, Mathers BM, Cowle B, Hagan H, Des Jarlais DC, Horyniak D, et al. Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews. Lancet 2011;378:571-583.
4. Mehta SH, Astemborski J, Kirk GD, Strathdee SA, Nelson K, Vlahov D, et al. Changes in blood-borne infection risk among injection drug users. J Infec Dis 2011;203:587-594.
5. Maher L, Li J, Jalaludin B, Chant KG, Kaldor JM. High hepatitis C incidence in new injecting drug users: a policy failure? Aust New Zealand J Pub Health 2007;31:30-35.
6. Hagan H, Pouget ER, Des Jarlais DC. A systematic review and meta-analysis of interventions to prevent hepatitis C virus infection in people who inject drugs. J Infec Dis 2011;204:74-83.
7. Van Den Berg C, Smit C, Brussel GV, Coutinho R, Prins M. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug users. Addiction 2007;102:1454-1462.
8. Turner K, Hutchinson S, Craine N, Hope V, Palmateer N, Vickerman P, et al. The impact of needle and syringe provision and opiate substitution therapy on the incidence of hepatitis C virus in injecting drug users: pooling of UK evidence. Addiction 2011;106:1978-1988.
9. Vickerman P, Martin N, Turner K, Hickman M. Can needle and syringe programmes and opiate substitution therapy achieve substantial reductions in HCV prevalence? Model projections for different epidemic settings. Addiction 2012;107:1984-1995.
10. Cohen M, Chen Y, McCauley M, Gamble T, Hosseinipour M, Kumarasamy N, et al. Prevention of HIV-1 infection with early antiretorival therapy. N Engl J Med 2011;365:493-505.
11. Cohen J. Halting HIV/AIDS epidemics. Science 2011;334:1338-1340.
12. Martin NK, Vickerman P, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. Can antiviral therapy for hepatitis C reduce the prevalence of HCV among injecting drug user populations? A modelling analysis of its prevention utility. J Hepatol 2011;54:1137-1144.
13. Martin NK, Vickerman P, Hickman M. Mathematical modelling of hepatitis C treatment for injecting drug users. J Theor Biol 2011;274:58-66.
14. Zeiler I, Langlands T, Murray JM, Ritter A. Optimal targeting of hepatitis C virus treatment among injecting drug users to those not enrolled in methadone maintenance programs. Drug Alcohol Depend 2010;110:228-233.
15. Vickerman P, Martin N, Hickman M. Can hepatitis C virus treatment be used as a prevention strategy? Additional model projections for Australia and elsewhere. Drug Alcohol Depend 2011;113:83-85.
16. Hellard M, Jenkinson R, Higgs P, Stoové M, Sacks-Davis R, Gold J, et al. Modelling antiviral treatment to prevent hepatitis C infection among people who inject drugs in Victoria, Australia. Med J Aust 2012;196:638-641.
17. Martin NK, Miners A, Vickerman P, Foster G, Hutchinson S, Goldberg D, et al. The cost-effectiveness of HCV antiviral treatment for injecting drug user populations. Hepatology 2012;55:49-57.
18. Grebely J, Raffa JD, Lai C, Krajden M, Kerr T, Fischer B, et al. Low uptake of treatment for hepatitis C virus infection in a large community-based study of inner city residents. J Viral Hepat 2009;16:352-358.
19. Iverson J, Maher L. Australian Needle and Syringe Program National Data Report 2007-2011. Kensington, Australia: The Kirby Institute; 2012.
20. Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med 2013;368:34-44.
21. Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, et al. Exploratory study of oral combination antiviral therapy for hepatitis C. N Engl J Med 2013;368:45-53.
22. Dore GJ. The changing therapeutic landscape for hepatitis C. Med J Aust 2012;196:629-632.
23. Dahari H, Ribeiro RM, Perelson AS. Triphasic decline of hepatitis C virus RNA during antiviral therapy. Hepatology 2007;46:16-21.
24. Liu L, Fisher B, Thomas D, Cox A, Ray S. Spontaneous clearance of primary acute hepatitis C virus infection correlated with high initial viral RNA level and rapid HVR1 evolution. Hepatology 2012;55:1684-1691.
25. Quinn TC, Wawer M, Sewankambo N, Serwadda D, Li C, Wabwire-Mangen F, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000;342:921-929.
26. Health Protection Scotland and the University of the West of Scotland. The Needle Exchange Surveillance Initiative (NESI): Prevalence of HCV, HIV and Injecting Risk Behaviours Among Injecting Drug Users Attending Needle Exchanges in Scotland, 2007. Glasgow, UK: Health Protection Scotland; 2008.
27. Iverson J, Topp L, Maher L. Australian NSP Survey National Data Report 1995-2010. Kensington, Australia: The Kirby Institute; 2011.
28. Kim C, Kerr T, Li K, Zhang R, Tyndall MW, Montaner J, et al. Unstable housing and hepatitis C incidence among injection drug users in a Canadian setting. BMC Public Health 2009;9:270.
29. Micallef JM, Kaldor JM, Dore GJ. Spontaneous viral clearance following hepatitis C infection: a systematic review of longitudinal studies. J Viral Hepat 2006;13:34-41.
30. Hickman M, Hope V, Coleman B, Parry J, Telfer M, Twigger J, et al. Assessing IDU prevalence and health consequences (HCV, overdose and drug-related mortality) in a primary care trust: implications for public health action. J Public Health 2009:1-9.
31. Cornish R, Macleod J, Strang J, Vickerman P, Hickman M. Risk of death during and after opiate substitution treatment in primary care: prospective observational study in UK General Practice Research Database. BMJ 2010;341.
32. Stoove MA, Dietze PM, Aitken CK, Jolley D. Mortality among injecting drug users in Melbourne: a 16-year follow-up of the Victorian Injecting Cohort Study (VICS). Drug Alcohol Depend 2008;96:281-285.
33. Urban Health Research Initiative of the British Columbia Centre for Excellence in HIV/AIDS. Drug situation in Vancouver. Vancouver, Canada: 2009. http://uhri.cfenet.ubc.ca/images/Documents/dsiv2009.pdf. Accessed April 2013.
34. Sweeting MJ, De Angelis D, Ades AE, Hickman M. Estimating the prevalence of ex-injecting drug use in the population. Stats Meth Med Res 2009;18:381-395.
35. Kimber J, Copeland L, Hickman M, Macleod J, McKenzie J, De Angelis D, et al. Survival and cessation in injecting drug users: prospective observational study of outcomes and effect of opiate substitution treatment. BMJ 2010;340:c3172.
36. University of the West of Scotland, Health Protection Scotland, and West of Scotland Specialist Virology Centre. The Needle Exchange Surveillance Initiative (NESI): Prevalence of HCV and Injecting Risk Behaviours Among Injecting Drug Users Attending Needle Exchanges in Scotland, 2008/2009; 2010. http://www.documents.hps.scot.nhs.uk/bbvsti/hepatitis-c/publications/nesi-needle-exchange.pdf. Accessed April 2013.
37. Aspinall A, Corson S, Doyle J, Grebely J, Hutchinson SJ, Dore GJ, et al. Treatment of HCV infection among people who are actively injecting drugs: a systematic review and meta-analysis. Clin Infect Dis. In press.
38. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011;364:2405-2416.
39. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011;364:1195-1206.
40. Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New protease inhibitors for the treatment of chronic hepatitis CA cost-effectiveness analysis. Ann Intern Med 2012;156:279-290.
41. WHO/UNAIDS/UNICEF. Global HIV/AIDS Response: Epidemic Update And Health Sector Progess Towards Universal Access; 2011.
42. Mathers BM, Degenhardt L, Ali H, Wiessing L, Hickman M, Mattick RP, et al. HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage. Lancet 2010;375:1014-1028.
43. Wood E, Kerr T, Marshall BDL, Li K, Zhang R, Hogg RS, et al. Longitudinal community plasma HIV-1 RNA concentrations and incidence of HIV-1 among injecting drug users: prospective cohort study. BMJ 2009;338.
44. Grebely J, Knight E, Genoway KA, Viljoen M, Khara M, Elliott D, et al. Optimizing assessment and treatment for hepatitis C virus infection in illicit drug users: a novel model incorporating multidisciplinary care and peer support. Eur J Gastroenterol Hepatol 2010;22:270-277.
45. Hallinan R, Byrne A, Agho K, Dore GJ. Referral for chronic hepatitis C treatment from a drug dependency treatment setting. Drug Alcohol Depend 2007;88:49-53.
46. Lindenburg CE, Lambers FA, Urbanus AT, Schinkel J, Jansen PL, Krol A, et al. Hepatitis C testing and treatment among active drug users in Amsterdam: results from the DUTCH-C project. Eur J Gastroenterol Hepatol 2011;23:23-31.
47. Harris KA Jr, Arnsten JH, Litwin AH. Successful integration of hepatitis C evaluation and treatment services with methadone maintenance. J Addict Med 2010;4:20-26.
48. Dimova RB, Zeremski M, Jacobson IM, Hagan H, Des Jarlais DC, Talal AH. Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis. Clin Infect Dis 2013;56:806-816.
49. Hellard M, Sacks-Davis R, Gold J. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 2009;49:561-573.
50. Lindenburg C, Krol A, Smit C, Buster M, Coutinho R, Prins M. Decline in HIV incidence and injecting, but not in sexual risk behaviour, seen in drug users in Amsterdam: a 19-year prospective cohort study. AIDS 2006;20:1771-1775.
51. Hay G, Gannon M, McKeganey N, Hutchinson S, Goldberg D. Estimating the National and Local Prevalence of Problem Drug Misuse in Scotland. University of Glasgow Centre for Drug Misuse Research and Health Protection Scotland. http://www.drugmisuse.isdscotland.org/publications/local/prevreport2004.pdf. Accessed on April 2013.
52. Kirwan A, Dietze D, Lloyd B. Victorian Drug Trends 2011: Findings from the Illicit Drug Reporting System (IDRS). Sydney, Australia: National Drug and Alcohol Research Centre, University of New South Wales; 2012.
53. McInnes C, Druyts E, Harvard S, Gilbert M, Tyndall M, Lima V, et al. HIV/AIDS in Vancouver, British Columbia: a growing epidemic. Harm Reduct J 2009;6:5.
54. Innes HA, Hutchinson SJ, Allen S, Bhattacharyya D, Bramley P, Carman B, et al. Ranking predictors of a sustained viral response for patients with chronic hepatitis C treated with pegylated interferon and ribavirin in Scotland. Eur J Gastroenterol Hepatol 2012;24:646-655.
55. Aitken CK, Lewis J, Tracy SL, Spelman T, Bowden DS, Bharadwaj M, et al. High incidence of hepatitis C virus reinfection in a cohort of injecting drug users. Hepatology 2008;48:1746-1752.
56. McCaw R, Moaven L, Locarnini S, Boden D. Hepatitis C virus genotypes in Australia. J Viral Hepat 1997;4:351-357.
57. Burns L, Randall D, Hall W, Law M, Butler T, Bell J, et al. Opioid agonist pharmacotherapy in New SouthWales from 1985 to 2006: patient characteristics and patterns and predictors of treatment retention. Addiction 2009;104:1363-1372.
58. Nosyk B, Marsh D, Sun H, Schechter M, Anis A. Trends in methadone maintenance treatment participation, retention, and compliance to dosing guidelines in British Columbia, Canada: 1996-2006. J Subst Abuse Treat 2010;39:22-31.
59. Allen EJ, Palmateer NE, Hutchinson SJ, Cameron S, Goldberg DJ, Taylor A. Association between harm reduction intervention uptake and recent hepatitis C infection among people who inject drugs attending sites that provide sterile injecting equipment in Scotland. Int J Drug Policy 2012;23:346-352.
60. O'Keefe D, Aitken CK, Higgs P, Dietze P. Concordance between self-reported and actual hepatitis C infection status in a cohort of people who inject drugs. Drug Alcohol Rev 2013;32:208-210.
61. Kemp PA, Neale J, Robertson M. Homelessness among problem drug users: prevalence, risk factors and trigger events. Health Soc Care Community 2006;14:319-328.
62. Mondelli M, Cerino A, Cividini A. Acute hepatitis C: diagnosis and management. J Hepatol 2005;42:5108-5114.
63. National Institute for Health and Clinical Excellence. Peginterferon alfa and Ribavirin for the Treatment of Mild Chronic Hepatitis C. NICE Technology Appraisal Guidance 106; 2006.